AL-001 is under clinical development by Alzamend Neuro and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AL-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Smarter leaders trust GlobalData

AL-001 overview

Liprosal is under development for the treatment of bipolar disorder, major depressive disorder, post traumatic stress disorder (PTSD), dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s disease. The drug candidate is a cocrystal based therapy comprising of lithium salicylate and L-proline. It is administered orally. Lithium acts by targeting glycogen synthase kinase 3 alpha, beta (GSK3A, GSK3B) and inositol mono/polyphosphatase (IMPase, IPPase). L-proline reduces the hygroscopic property of salicylate salt. The drug candidate was also under development for fragile x syndrome.

Alzamend Neuro overview

Alzamend Neuro is a biotechnology company, based in the US. The company develops and commercializes drugs, treatments and cures for Alzheimer’s disease.

For a complete picture of AL-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.